Unlike the situation in endometrial carcinoma, the circulating levels of leptin in patients with ovarian malignancies generally have been shown to be lower in comparison with healthy or non-cancer controls (Sen et al., 2011; Jin et al., 2016; Horala et al., 2017). This evidence concerns the gene LEP and endometrial carcinoma.